Child of Coefficient Giving
Metadata
| Source Table | grants |
| Source ID | 7_IZW0438k |
| Description | to Novartis, USD 2500000, 2024-10 |
| Source URL | coefficientgiving.org/funds/ |
| Parent | Coefficient Giving |
| Children | — |
| Created | Mar 12, 2026, 5:54 AM |
| Updated | Mar 22, 2026, 2:59 AM |
| Synced | Mar 19, 2026, 8:57 PM |
Record Data
id | 7_IZW0438k |
organizationId | Coefficient Giving(organization) |
granteeId | Novartis |
orgEntityId | Coefficient Giving(organization) |
orgDisplayName | — |
granteeEntityId | — |
granteeDisplayName | Novartis |
name | Novartis — Cryptosporidiosis Challenge Trial |
amount | 2500000 |
currency | USD |
period | — |
date | 2024-10 |
status | — |
source | coefficientgiving.org/funds/ |
notes | [Scientific Research] Open Philanthropy recommended a grant of $2,500,000 over two years to Novartis to support a Phase IIa challenge trial of a new drug, ED1048, for the treatment of cryptosporidiosis. Cryptosporidiosis is caused by the Cryptosporidium parasite. The parasite is widespread globally… |
programId | B4pZkOtjSk |
dataSourceId | — |
Source Check Verdicts
confirmed95% confidence
Last checked: 7/20/2026
1 → confirmed
Debug info
Thing ID: 7_IZW0438k
Source Table: grants
Source ID: 7_IZW0438k
Parent Thing ID: sid_ULjDXpSLCI